

Status: Currently Official on 13-Feb-2025
 Official Date: Official Prior to 2013
 Document Type: USP Monographs
 DocId: GUID-387E05D7-3C78-45F2-BB6E-CB64AADE6010_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M898_01_01
 DOI Ref: gau0q

© 2025 USPC
 Do not distribute

Acyclovir Oral Suspension

DEFINITION

Acyclovir Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of acyclovir ($C_8H_{11}N_5O_3$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Mobile phase: 0.02 M acetic acid

System suitability solution A: 0.1 mg/mL each of [USP Acyclovir RS](#) and guanine in 0.1 N sodium hydroxide

System suitability solution B: 2.0 µg/mL of guanine in 0.1 N sodium hydroxide

Standard solution: 0.1 mg/mL of [USP Acyclovir RS](#) in 0.1 N sodium hydroxide

Sample stock solution: Nominally 1 mg/mL of acyclovir prepared as follows. Transfer an amount of well-shaken Oral Suspension equivalent to 200 mg of acyclovir to a 200-mL volumetric flask. Add 100 mL of 0.1 N sodium hydroxide, shake by mechanical means for 15 min, and sonicate, if necessary, to dissolve the Oral Suspension completely. Dilute with 0.1 N sodium hydroxide to volume.

Sample solution: Transfer 10.0 mL of the *Sample stock solution* to a 100-mL volumetric flask, and dilute with water to volume.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*).

Mode: LC

Detector: UV 254 nm

Column: 4.6-mm × 25-cm; packing L1

Flow rate: 3 mL/min

Injection volume: 20 µL

System suitability

Samples: *System suitability solution A* and *System suitability solution B*

[NOTE—The relative retention times for guanine and acyclovir are about 0.6 and 1.0, respectively, in *System suitability solution A*.]

Suitability requirements

Resolution: NLT 2.0 between guanine and acyclovir, *System suitability solution A*

Relative standard deviation: NMT 2.0% for replicate injections for the acyclovir peak, *System suitability solution A*

Relative standard deviation: NMT 2.0% for replicate injections, *System suitability solution B*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acyclovir ($C_8H_{11}N_5O_3$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Acyclovir RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of acyclovir in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

IMPURITIES

• LIMIT OF GUANINE

Mobile phase, System suitability solution A, System suitability solution B, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.

Standard solution: 2.0 µg/mL of guanine in 0.1 M sodium hydroxide

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of guanine in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response for guanine from the *Sample solution*

r_S = peak response for guanine from the *Standard solution*

C_S = concentration of guanine in the *Standard solution* (mg/mL)

C_U = nominal concentration of acyclovir in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 2.0%

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): Its total count does not exceed 10^1 cfu/mL, and it meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli*.
- [pH \(791\)](#): 4.5–7.0

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements for Oral Suspension packaged in single-unit containers
- [DELIVERABLE VOLUME \(698\)](#): Meets the requirements for Oral Suspension packaged in multiple-unit containers

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store between 15° and 25°. Protect from light.
- [USP REFERENCE STANDARDS \(11\)](#)
[USP Acyclovir RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ACYCLOVIR ORAL SUSPENSION	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 30(2)

Current DocID: GUID-387E05D7-3C78-45F2-BB6E-CB64AADE6010_1_en-US

DOI: https://doi.org/10.31003/USPNF_M898_01_01

DOI ref: [gau0q](#)